Tag: immunotherapies

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research

First CD5 Targeted Therapy Commercial Launch Expected By 2030 Says Kuick Research 

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, June 19, 2025 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies...